Tag Archives: preserved ejection fraction

Introduction Heart failure is a significant and rising public health problem affecting 900,000 people in the UK, and accounts for 5% of all emergency admissions.1 This rising trend is set to continue as the average age of the population increases.1-3 It is estimated that the proportion of patients with heart failure with preserved ejection fraction (HFPEF) is between 30% and 50%.4-9 As a result, in recent years, more attention has been paid to this cohort of patients. However, there is still limited information regarding outcomes and treatment for these patients. Previous reports have shown that patients that have HFPEF are more likely to be

WOEST: aspirin not required for stent patients on oral anticoagulants  A strategy of using clopidogrel as a single antiplatelet drug for patients receiving a drug-eluting stent who are also taking an oral anticoagulant appears safe and can reduce bleeding, the results of the WOEST study suggest. How to treat patients on anticoagulation when they receive a stent is fraught with difficulty as giving the normal dual antiplatelet therapy with aspirin and clopidogrel means they will be taking three anti-clotting agents which could increase bleeding complications to a dangerous level. But no randomised clinical trials have ever investigated whethe